Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry ...

The biotech sector staged a robust comeback in 2025, with the Nasdaq Biotechnology Index climbing 33.8%. Although concerns about potential high tariffs initially hurt the industry, sentiment among ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one ...

The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, ...

The tenth stock on our list is Legend Biotech Corporation (NASDAQ:LEGN). TheFly reported on January 22 that H.C. Wainwright lowered LEGN’s price target to $50 from $60 but kept a Buy rating, noting Q4 ...

After a weak first half, the drug and biotech sector regained momentum in the latter part of 2025, setting the stage for a strong year for select stocks. Improved policy clarity following most large ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is placed sixth on our list of best biotech stocks under $20. TheFly reported on January 5 that Wells Fargo raised its price target on TSHA to $11 from $8 and ...